Viscosupplementation Market Share

Global Viscosupplementation Market Overview

The Viscosupplementation Market Size was valued at USD 2.337 billion in 2023. The Viscosupplementation market industry is projected to grow from USD 2.602 Billion in 2024 to USD 5.513 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.84% during the forecast period (2024 - 2032). The rising popularity of minimally invasive procedures and the increasing geriatric populationare the key market drivers enhancing the market growth.

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

In December 2021, Avanos Medical, Inc. made a formal agreement to purchase OrthogenRx, Inc., a rising company specializing in viscosupplementation therapies for alleviating knee osteoarthritis (OA) pain. The acquisition will be completed for a total amount of $160 million. The purchase price comprises $130 million in cash upon completion, along with a further $30 million in conditional cash payment, which will be made upon reaching specific growth targets associated with the company's commercial hyaluronic acid (HA) therapeutic products, GenVisc® 850 and TriVisc®. The utilization of HA therapy for treating knee pain caused by OA promises a lucrative business prospect amounting to $1 billion in the United States. Avanos will enhance its pain portfolio for knee osteoarthritis (OA) by including GenVisc 850 and TriVisc. Both of these treatments have been approved by the U.S. Food and Drug Administration and are specifically indicated for patients who have not responded well to conservative, non-pharmacologic therapy and simple analgesics.

Viscosupplementation Market Trends

• The increasing incidence of knee osteoarthritis is driving the market growth.

Knee osteoarthritis is among the most common ailments prevalent among the geriatric population. The rising cases of cardiovascular diseases, depression, obesity, renal failure, hypertension, and gastrointestinal bleeding are expected to grow the demand for viscosupplement therapy, augmenting the market CAGR during the assessment period.

Additionally, the established players in the market are focusing on developing cross-linked hyaluronic acid to provide instant relief from pain. The ongoing advancement will offer a significant opportunity to augment the viscosupplementation market share. Moreover, the reimbursement scenario is likely to become favorable ly, making treatment for osteoarthritis affordable.

In the U.S., products such as Orthovisc, Supartz Hyalgan, Synvisc, and others, are approved by the FDA as Class III medical devices to treat OA knee pain and are reimbursed by medicaid, medicare, and other state healthcare programs. France also has a well-defined reimbursement policy for viscosupplements. In France, out of the 13 products available for the treatment of knee osteoarthritis, 12 are reimbursed up to 65% by social security. Thus, favorable reimbursement policies concerning the senior population are expected to offer growth of the Viscosupplementation market revenue.

Viscosupplementation Market Segment Insights

Viscosupplementation Type Insights

Based on type, the Viscosupplementation market segmentation includes stabilized hyaluronic Acid, standard hyaluronic acid. The stabilized hyaluronic acid segment dominated the market, owing to the higher quality of the product.

Figure 1 Viscosupplementation Market, by Procedure Type, 2022&2032 (USD billion)

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

Viscosupplementation Procedure Type Insights

Based on procedure type, the Viscosupplementation market segmentation includes a Three-injection procedure. The three-injection procedure segment dominated the marketdue to the lower cost of these products and the shorter treatment regimen.The three-injection procedure is the leading segment, likely to grow at the highest CAGR to reach USD 2602.58 million by the end of 2023.

Viscosupplementation Regional Insights

By Region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American viscosupplementation market will dominate, owing to the growing preference for short treatment regimens, even though high priced, and the growing prevalence of target diseases, such as osteoarthritis, will boost the market growth in this Region.

Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2 VISCOSUPPLEMENTATION MARKET SHARE BY REGION 2022 (%)

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe's Viscosupplementation market accounts for the second-largest market share due to the rising geriatric population. The market in the Region is likely to show a significant rise owing to the growing product innovation in the coming period. Further, the German Viscosupplementation market held the largest market share, and the UK Viscosupplementation market was the fastest-growing market in the European Region.

The Asia-Pacific Viscosupplementation Market is expected to grow at the fastest CAGR from 2024 to 2032. This is due tothe increasing initiatives the developing countries take to develop their healthcare infrastructure, which will likely augment regional trade during the projection timeframe. Moreover, China’s Viscosupplementation market held the largest market share, and the Indian Viscosupplementation market was the fastest-growing market in the Asia-Pacific region.

Viscosupplementation Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development to expand their product lines, which will help the Viscosupplementation market grow even more. Market participants are also undertaking various strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. The Viscosupplementation industry must offer cost-effective items to expand and survive in a more competitive and rising market climate.

Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the Viscosupplementation industry to benefit clients and increase the market sector. In recent years, the Viscosupplementation industry has offered some of the most significant advantages to medicine. Major players in the Viscosupplementation market, including others, are attempting to increase market demand by investing in research and development operations.

OrthogenRx, Inc., now An Avanos Company, is a medical device company focused on developing and commercializing treatments for musculoskeletal conditions, including osteoarthritis (OA). We are headquartered in Doylestown, PA, an early-stage private medical device company. Our first product, GenVisc 850 (sodium hyaluronate), is the only five-injection hyaluronic acid product produced from the non-avian source material. OrthogenRx, a leader in viscosupplementation therapy for the treatment of knee osteoarthritis (OA) pain, has agreed to be acquired by Avanos Medical, Inc. for $130 million in cash and up to $30 million in contingent cash consideration. The deal was finalized on January 20, 2022.

Juniper Biologics is a science-led healthcare company focused on delivering novel therapies to improve patients' health and quality of life by building a growing presence in oncology, rare/orphan diseases, and gene therapy. Juniper Biologics signed a licensing deal with Kolon Life Sciences to develop and commercialize, TissueGene-C low dose (TG-C LD), non-surgical investigational therapy administered as a single intra-articular injection, to treat knee osteoarthritis. Under the licensing deal, Juniper will develop and market gene therapy to medical professionals and hospitals in Asia-Pacific, the Middle East, and Africa.

Key Companies in the Viscosupplementation market include

• Allergan


• Sanofi


• Hoffmann-La Roche


• Smith & Nephew Plc


• Zimmer Biomet


• Anika Therapeutics Inc.


• Ferring B.V.


• Bioventus


• FidiaFarmaceutici S.P.A.

Viscosupplementation Industry Developments

April 2022 Juniper Biologics signed a licensing deal with Kolon Life Sciences to develop and commercialize, TissueGene-C low dose (TG-C LD), non-surgical investigational therapy administered as a single intra-articular injection, to treat knee osteoarthritis. Under the licensing deal, Juniper will develop and market gene therapy to medical professionals and hospitals in Asia-Pacific, the Middle East, and Africa.

May 2021 Ono Pharmaceutical Co., Ltd. and Seikagaku Corporation launched JOYCLU 30mg intra-articular injection, a joint function improvement agent, for which Seikagaku received manufacturing and marketing approval, in Japan, in March 2021.

Viscosupplementation Market Segmentation

Viscosupplementation Hyaluronic Acid Type Outlook

• Stabilized Hyaluronic Acid


• Standard hyaluronic

Viscosupplementation Procedure Type Outlook

• Three-Injection Procedure

Viscosupplementation Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America